Drugmakers Point Finger at Middlemen for Rising Drug Prices

For many years, drugmakers defended the practice of privately negotiating rebates as a market-based alternative to government-run price negotiations. They also prospered under the rebate system, which largely failed to curb drug-price increases. Now, with drugmakers under scrutiny for sometimes-dramatic price increases, some industry executives say the system no longer works efficiently and is ripe for reform.